Sunday, June 21, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 460 of 1,261
  1. US 10480031

    Method for generating Retinal Pigment Epithelium (RPE) cells from Induced Pluripotent Stem Cells (IPSCs)

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  2. US 10479993

    Modulation of signal transducer and activator of transcription 3 (STAT3) expression

    Ionis Pharmaceuticals, Inc. · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  3. US 10479980

    Artificial ovary

    Northwestern University · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  4. US 10479868

    Polymeric stabilizing formulations

    Nano Precision Medical, Inc. · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  5. US 10479839

    Internalizing human monoclonal antibodies targeting prostate cancer cells in situ

    The Regents of the University of California · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  6. US 10479830

    Anti eotaxin-2 antibodies that recognize additional CCR3-binding chemokines

    CHEMOMAB LTD. · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  7. US 10479798

    Six-membered ring benzo derivatives as DPP-4 inhibitor and use thereof

    East China University of Science and Technology · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  8. US 10479825

    Antibody-mediated neutralization of Marburg virus

    The Board of Regents of the University of Texas System · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  9. US 10478508

    Compositions, methods and uses for alpha-1 antitrypsin fusion molecules

    The Regents of the University of Colorado, a Body Corporate · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  10. US 10478505

    Edible oils to enhance delivery of orally administered steroids

    The Regents of the University of California · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  11. US 10479783

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  12. US 10478513

    Nitroxide containing amyloid binding agents for imaging and therapeutic uses

    The Regents of the University of California · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  13. US 10478500

    Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression

    Alnylam Pharmaceuticals, Inc. · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  14. US 10478485

    Methods and compositions to prevent or treat bacterial infections

    The Board of Regents of the University of Texas System · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  15. US 10479784

    Substituted pyrazin-2-amines as inhibitors of ATR kinase

    Vertex Pharmaceuticals Incorporated · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  16. US 10478435

    Use of CRAC channel inhibitors for the treatment of stroke and traumatic brain injury

    United States Government as represented by the Department of Veterans Affairs · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  17. US 10478461

    Cellular extracts

    REGENICS AS · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  18. CA 3094896

    COMPOSES DE 1H-INDAZOLE-3-CARBOXAMIDE UTILISES EN TANT QU'INHIBITEURS DE LA GLYCOGENE SYNTHASE KINASE 3 BETA

    ACRAF [IT] · Granted Nov 14, 2019 · Expires Nov 9, 2039

    granted
  19. US 10471061

    Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted
  20. US 10471142

    Combination therapy using immunoglobulin and C1-Inhibitor

    THE GOVERNMENT OF THE UNITED STATES OF AMERICA · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted
  21. US 10472357

    Triazolopyridine compounds and methods for the treatment of cystic fibrosis

    Flatley Discovery Lab, LLC · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted
  22. US 10471014

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted
  23. US 10471144

    Combination of local rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer

    Provectus Pharmatech, Inc. · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted
  24. US 10472363

    SGC stimulators

    Cyclerion Therapeutics, Inc. · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.